Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Símbolo de cotizaciónACOG
Nombre de la empresaAlpha Cognition Inc
Fecha de salida a bolsaJun 09, 2021
Director ejecutivoMcfadden (Michael E)
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 09
Direcciónc/o 1200 - 750 West Pender Street
CiudadVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV6C 2T8
Teléfono16045649244
Sitio Webhttps://www.alphacognition.com/
Símbolo de cotizaciónACOG
Fecha de salida a bolsaJun 09, 2021
Director ejecutivoMcfadden (Michael E)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos